Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].

又见闪崩！ 目前，该公司董事会已决定将上述决定提交上市委员会复核，并正在编制相关要求函件。 此前，该公司以每股0.415港元配售最多1.45亿股的配售协议已失效。原因是协议中的先决条件未能在2025年9月11日或之前达成。因此，此次配售事项将不会进行， 配售代理及公司双方的责任均已终止，且双方不得就此协议向对方提出任何索赔。 曾一度暴涨 今日早盘，港股星太链集团直线闪崩，跌幅一度超过70%。 据星太链集团公告，2025年11月17日公司公告显示，于2025年11月14日接获联交所决定，因未能维持足够运营水平和足够价值的资产，股份将于2025年11月26日暂 停买卖。 该公司此前发布公告称，原定以每股0.415港元配售最多1.45亿股的配售协议已失效。原因是协议中的先决条件未能在2025年9月11日或之前达成。因此，此次配售事 项将不会进行，配售代理及公司双方的责任均已终止，且双方不得就此协议向对方提出任何索赔。 暴击来了 今早，星太链集团发布公告称，2025年11月14日，公司接获联交所的函件，通知公司其作出的决定，即经考虑联交所可得资料(包括公司的提呈文件)，根据第13.24 条的规定，公司未能维持足够的运 ...